• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Biocon Share Price

    Biocon Share PriceBiocon

    Large Cap 14.8k Result
    ₹240.05
    1.05 (0.44%)
    • Advice
    • Hold
    As on 12 December, 2023 | 03:38 BSE: 532523 NSE: BIOCONISIN: INE376G01013

    Biocon Performance

    Day Range

    • Low 237.65
    • High 240.55
    ₹ 240.05

    52 Week Range

    • Low 191.55
    • High 279.90
    ₹ 240.05
    • Open Price239.80
    • Previous Close239.00
    • Volume1612669

    Start SIP in Biocon

    Start SIP

    Biocon Share Price

    • Over 1 Month 5.56%
    • Over 3 Month -13.15%
    • Over 6 Month -0.44%
    • Over 1 Year -11.83%

    Biocon Key Statistics

    P/E Ratio 57.8
    PEG Ratio -3
    Market Cap Cr 28,820
    Price to Book Ratio 1.3
    EPS -0.1
    Dividend 0.6
    Relative Strength Index 54.85
    Money Flow Index 57.02
    MACD Signal 0.4
    Average True Range 4.75

    Biocon F&O

    Biocon Futures
    Biocon Option Chain

    Biocon Investment Rating

    • Master Rating:

    • Biocon (Nse) has an operating revenue of Rs. 13,599.90 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 10% is healthy, ROE of 2% is fair but needs improvement. The company has a debt to equity of 86%, which is bit higher. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 60 which is a FAIR score but needs to improve its earnings, a RS Rating of 16 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 117 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Biocon Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 519513507555490442518
    Operating Expenses Qtr Cr 452441551518462439491
    Operating Profit Qtr Cr 6772-443728327
    Depreciation Qtr Cr 31302929302928
    Interest Qtr Cr 55484821000
    Tax Qtr Cr 113-1511119821
    Net Profit Qtr Cr 35471,811359881538
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 2,2641,925
    Operating Expenses Annual Cr 1,9691,677
    Operating Profit Annual in Cr 2461
    Depreciation Cr 117108
    Interest Annual Cr 700
    Tax Annual Cr 12354
    Net Profit Annual Cr 2,84886
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 21948
    Cash from Investing Activity Annual Cr -1,178-306
    Cash from Financing Annual Activity Cr 1,039112
    Net Cash Flow Annual Cr 81-146
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 10,9168,093
    Fixed Assets Annual Cr 1,3051,155
    Total Non Current Assets Annual Cr 10,4646,467
    Total Current Assets Annual Cr 2,5662,402
    Total Assets Annual Cr 13,0308,869
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 9167
    ROE Annual % 261
    ROCE Annual % 12
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1514
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 3,4623,4233,7742,9412,3202,1402,409
    Operating Expenses Qtr Cr 2,7212,7082,7772,2971,8491,7401,817
    Operating Profit Qtr Cr 742714997644471399592
    Depreciation Qtr Cr 389358364301231218212
    Interest Qtr Cr 248233249120302011
    Tax Qtr Cr 423582-51473059
    Net Profit Qtr Cr 126101313-4247144239
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 11,5508,397
    Operating Expenses Annual Cr 8,6636,214
    Operating Profit Annual in Cr 2,5121,970
    Depreciation Cr 1,113814
    Interest Annual Cr 41968
    Tax Annual Cr 254212
    Net Profit Annual Cr 463648
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 1,8531,177
    Cash from Investing Activity Annual Cr -14,282-1,699
    Cash from Financing Annual Activity Cr 13,049242
    Net Cash Flow Annual Cr 619-280
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 17,8678,433
    Fixed Assets Annual Cr 20,64910,653
    Total Non Current Assets Annual Cr 39,70912,012
    Total Current Assets Annual Cr 12,3348,382
    Total Assets Annual Cr 52,04320,394
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 18779
    ROE Annual % 38
    ROCE Annual % 48
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2627
    Invest in Biocon

    Biocon Technicals

    EMA & SMA

    Current Price
    ₹240.05
    1.05 (0.44%)
    pointer
    • Bullish Moving Average
    • ___
    • 8
    • Bearish Moving Average
    • ___
    • 8
    • 20 Day
    • ₹237.31
    • 50 Day
    • ₹240.08
    • 100 Day
    • ₹244.50
    • 200 Day
    • ₹250.79
    • 20 Day
    • ₹236.24
    • 50 Day
    • ₹239.35
    • 100 Day
    • ₹250.71
    • 200 Day
    • ₹242.45

    Biocon Resistance and Support

    PIVOT
    ₹239.42
    Resistance
    First Resistance 241.18
    Second Resistance 242.32
    Third Resistance 244.08
    RSI 54.85
    MFI 57.02
    MACD Single Line 0.40
    MACD 1.42
    Support
    First Resistance 238.28
    Second Resistance 236.52
    Third Resistance 235.38

    Biocon Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 1,670,897 78,665,831 47.08
    Week 2,206,668 110,355,467 50.01
    1 Month 3,007,329 132,563,040 44.08
    6 Month 3,697,518 167,534,550 45.31

    Biocon Result Highlights

    Biocon Synopsis

    NSE-Medical-Biomed/Biotech

    Biocon is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1992.90 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2023. Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417.
    Market Cap 28,701
    Sales 2,094
    Shares in Float 46.82
    No of funds 268
    Yield 0.63
    Book Value 2.64
    U/D Vol ratio 0.9
    LTDebt / Equity 12
    Alpha -0.09
    Beta 0.86

    Biocon

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 60.64%60.64%60.64%60.64%
    Mutual Funds 8.26%7.47%7.19%3.95%
    Insurance Companies 5.76%5.09%4.68%4.68%
    Foreign Portfolio Investors 7.97%9.52%10.2%14.42%
    Financial Institutions/ Banks
    Individual Investors 13.61%13.34%13.2%12.47%
    Others 3.76%3.94%4.09%3.84%

    Biocon Management

    Name Designation
    Ms. Kiran Mazumdar Shaw Executive Chairperson
    Mr. Siddharth Mittal Managing Director & CEO
    Prof. Ravi Rasendra Mazumdar Non Exe.Non Ind.Director
    Mr. Eric Vivek Mazumdar Non Exe.Non Ind.Director
    Mr. Meleveetil Damodaran Lead Independent Director
    Dr. Vijay Kumar Kuchroo Independent Director
    Mr. Bobby Kanubhai Parikh Independent Director
    Mr. Peter John Bains Independent Director
    Mr. Naina Lal Kidwai Independent Director

    Biocon Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Biocon Corporate Action

    Date Purpose Remarks
    2023-11-10 Quarterly Results
    2023-08-10 Quarterly Results
    2023-05-23 Audited Results & Final Dividend
    2023-04-26 Others To consider, Fund Raising. per share(20%)Final Dividend (Rs.0.5000 per share(10%)Final Dividend (Post Bonus Issue))
    2023-02-14 Quarterly Results
    Date Purpose Remarks
    2023-07-07 FINAL Rs.1.50 per share(30%)Final Dividend
    2022-07-01 FINAL Rs.0.50 per share(10%)Final Dividend

    Biocon MF Shareholding

    Name Amount(cr)
    Mirae Asset Large Cap Fund Regular Growth 34,377
    Kotak Equity Arbitrage Fund Growth 28,958
    ICICI Prudential Multi-Asset Fund Growth 24,931
    SBI Balanced Advantage Fund Regular Growth 24,344
    SBI Arbitrage Opportunities Fund Regular Growth 22,370

    About Biocon

    Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bangalore, India. The company has more than 13,500  employees. It focuses on all phases of the product cycle from researching to development and then introducing them to the market.  They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies. 

    Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine), etc. 

    Biocon FAQs

    What is Share Price of Biocon ?

    Biocon share price is ₹240 As on 12 December, 2023 | 03:24

    What is the Market Cap of Biocon ?

    The Market Cap of Biocon is ₹28820.4 Cr As on 12 December, 2023 | 03:24

    What is the P/E ratio of Biocon ?

    The P/E ratio of Biocon is 57.8 As on 12 December, 2023 | 03:24

    What is the PB ratio of Biocon ?

    The PB ratio of Biocon is 1.3 As on 12 December, 2023 | 03:24

    Is it a good time to invest in Biocon Limited?

    Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.

    How many times has Biocon Limited given dividends since 2004?

    Biocon Ltd. has declared 17 dividends since July 1, 2004.

    What is the stock price CAGR of Biocon Limited?

    The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.

    What is the debt-to-equity ratio of Biocon Limited?

    The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.

    What is the ROE of the Biocon Limited?

    The ROE of Biocon Limited is 9% which is fair but needs improvement.

    Who is the Managing Director of Biocon Limited?

    Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.

    Is Biocon a good stock to buy?

    According to the record analysis of moneyworks4me, Biocom limited is an average quality company. 

    How to buy shares of Biocon Ltd?

    The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.